A Controlled Study of a Group Mindfulness Intervention for Individuals Living With Inflammatory Bowel Disease.

Abstract:

BACKGROUND:This study aimed to evaluate the feasibility, acceptability, and effectiveness of a mindfulness-based intervention for patients with inflammatory bowel disease (MI-IBD). DESIGN:Treatment-as-usual control versus mindfulness-based stress reduction intervention. METHODS:Sixty patients participated in either the MI-IBD (n = 33) or treatment-as-usual group (n = 27) conditions. The MI-IBD consisted of an 8-week mindfulness-based stress reduction training group. Outcome measures were administered at baseline (before intervention), immediately after intervention, and 6 months after intervention. Primary outcomes included measures of quality of life, psychological distress (depression and anxiety), and mindfulness. Data for MI-IBD group participants also included weekly attendance, daily minutes meditated, and satisfaction with the program. RESULTS:There were no baseline differences between intervention and control groups on demographic variables or inflammatory bowel disease severity. Compared with the control group, the MI-IBD group reported significantly greater improvements in anxiety, quality of life, and mindfulness at after intervention, with reduction in depression and improvements in quality of life and mindfulness maintained at 6 months after intervention. CONCLUSIONS:Results demonstrate the feasibility, acceptability, and efficacy of a mindfulness intervention for patients with inflammatory bowel disease, with medium-to-large effects on psychological distress, quality of life, and mindfulness.

journal_name

Inflamm Bowel Dis

authors

Neilson K,Ftanou M,Monshat K,Salzberg M,Bell S,Kamm MA,Connell W,Knowles SR,Sevar K,Mancuso SG,Castle D

doi

10.1097/MIB.0000000000000629

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

694-701

issue

3

eissn

1078-0998

issn

1536-4844

journal_volume

22

pub_type

杂志文章
  • Antiviral Therapy in Steroid-refractory Ulcerative Colitis with Cytomegalovirus: Systematic Review and Meta-analysis.

    abstract:BACKGROUND:The role of antiviral therapy in patients with ulcerative colitis (UC) with cytomegalovirus (CMV) remains unclear. We therefore performed a systematic review and meta-analysis to assess the association between antiviral therapy and the risk of colectomy. METHODS:Multiple electronic databases were searched s...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/MIB.0000000000000489

    authors: Shukla T,Singh S,Loftus EV Jr,Bruining DH,McCurdy JD

    更新日期:2015-11-01 00:00:00

  • Presenting symptoms and diagnostic lag in children with inflammatory bowel disease.

    abstract::Presenting symptoms and their duration may affect the time that elapses prior to definitive diagnosis of inflammatory bowel disease (IBD). This study was undertaken to determine the mean duration of presenting symptoms and diagnostic lag in children with IBD. The medical records of all patients less than 19 years of a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-199908000-00002

    authors: Heikenen JB,Werlin SL,Brown CW,Balint JP

    更新日期:1999-08-01 00:00:00

  • Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn's disease.

    abstract:BACKGROUND:Inflammatory bowel disease affects the quality of a patient's life in many ways, but no validated instrument for measuring disease-specific quality of life in these patients is available for use in Mainland China. The aim of our study was to develop and validate the Mainland Chinese translation of the Inflam...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20128

    authors: Ren WH,Lai M,Chen Y,Irvine EJ,Zhou YX

    更新日期:2007-07-01 00:00:00

  • Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients.

    abstract:Introduction:A new clinician-administered inflammatory bowel disease (IBD) Disability Index (IBDDI) was recently developed and validated among a population in France. We aimed to validate the IBDDI in a North American setting and adapt for use as a self-report tool. Methods:Persons 18-65 years old from the population-...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izx063

    authors: Shafer LA,Walker JR,Chhibba T,Ivekovic M,Singh H,Targownik LE,Peyrin-Biroulet L,Gower-Rousseau C,Sarter H,Bernstein CN

    更新日期:2018-03-19 00:00:00

  • Thromboembolism in pediatric inflammatory bowel disease: systematic review.

    abstract:BACKGROUND:Several studies suggest an increased risk of venous and arterial thromboembolism (TE) in adults with inflammatory bowel disease (IBD) compared to the general population. We performed a systematic review of studies on incidence and characteristic of TE in children with IBD. METHODS:We searched Medline, LILAC...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21563

    authors: Lazzerini M,Bramuzzo M,Maschio M,Martelossi S,Ventura A

    更新日期:2011-10-01 00:00:00

  • Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-induced Colitis.

    abstract:BACKGROUND:Iron is an important nutrient for both the host and colonizing bacteria. Oral iron supplementation may impact the composition of the microbiota and can be particularly damaging to patients suffering from inflammatory bowel disease (IBD). However, patients with IBD may require iron supplementation to treat th...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001089

    authors: Constante M,Fragoso G,Lupien-Meilleur J,Calvé A,Santos MM

    更新日期:2017-05-01 00:00:00

  • Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease.

    abstract:BACKGROUND:Mucosa-associated Escherichia coli are abundant in inflammatory bowel disease (IBD), but whether these bacteria gain intracellular access within the mucosa is uncertain. If E. coli does gain intracellular access, the contribution of bacterial pathogenicity to this requires further elucidation. This study aim...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e3182a38a92

    authors: Elliott TR,Hudspith BN,Wu G,Cooley M,Parkes G,Quiñones B,Randall L,Mandrell RE,Fagerquist CK,Brostoff J,Rayment NB,Boussioutas A,Petrovska L,Sanderson JD

    更新日期:2013-10-01 00:00:00

  • Utilization of influenza immunization in adults with Crohn's disease-a longitudinal, population-based study.

    abstract:BACKGROUND:The incidence of vaccine-preventable disease is increasing. Several guidelines recommend annual influenza vaccination for patients with inflammatory bowel disease. METHODS:Using the Business Objects database of Clalit Health Services in the Tel Aviv district we identified all patients older than 18 years wi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.MIB.0000440816.76627.bf

    authors: Boltin D,Gingold-Belfer R,Kimchi NA,Ben-Bassat O,Niv Y,Birkenfeld S

    更新日期:2014-02-01 00:00:00

  • Therapeutic potential of helminth soluble proteins in TNBS-induced colitis in mice.

    abstract:BACKGROUND:The hygiene hypothesis suggests an inverse relationship between the incidence of parasitic infections and chronic inflammatory bowel diseases (IBD). We investigated the therapeutic potential of Schistosoma mansoni and Ancylostoma caninum soluble proteins on experimental colitis in mice. METHODS:Colitis was ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20787

    authors: Ruyssers NE,De Winter BY,De Man JG,Loukas A,Pearson MS,Weinstock JV,Van den Bossche RM,Martinet W,Pelckmans PA,Moreels TG

    更新日期:2009-04-01 00:00:00

  • Intestinal Inflammation and Tumor Burden as Determinants for Bone Fragility in APC-Driven Tumorigenesis.

    abstract:Background:Colorectal cancer (CRC) is a major cause of cancer-related deaths, and tumor-related comorbidities additionally lower life quality and survival. Mutations in the tumor suppressor adenomatous polyposis coli (APC) are associated with sporadic CRC and familial adenomatous polyposis (FAP), which results in the g...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy234

    authors: Saul D,Schilling AF,Kosinsky RL

    更新日期:2018-10-12 00:00:00

  • Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease.

    abstract:BACKGROUND:Obesity is associated with systemic and intestine-specific inflammation and alterations in gut microbiota, which in turn impact mucosal immunity. Nonetheless, a specific role of obesity and its interaction with genetics in the progression of Crohn's disease (CD) is unclear. METHODS:We conducted a cross-sect...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000498

    authors: Pringle PL,Stewart KO,Peloquin JM,Sturgeon HC,Nguyen D,Sauk J,Garber JJ,Yajnik V,Ananthakrishnan AN,Chan AT,Xavier RJ,Khalili H

    更新日期:2015-10-01 00:00:00

  • Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.

    abstract:BACKGROUND:Though vedolizumab has received regulatory approval for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) in adults, there is increasing off-label use in children. AIMS:To describe the experience with vedolizumab in pediatric inflammatory bowel disease (IBD) patients at 3 tertiary IBD center...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000865

    authors: Singh N,Rabizadeh S,Jossen J,Pittman N,Check M,Hashemi G,Phan BL,Hyams JS,Dubinsky MC

    更新日期:2016-09-01 00:00:00

  • Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

    abstract:BACKGROUND:PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS:Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izz008

    authors: Loftus EV,Reinisch W,Panaccione R,Berg S,Alperovich G,Bereswill M,Kalabic J,Petersson J,Thakkar R,Robinson AM,D'Haens G

    更新日期:2019-08-20 00:00:00

  • Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.

    abstract:BACKGROUND:Optimal levels of adalimumab (ADA) have not been defined according to the ultimate goal of inflammatory bowel disease treatment--histologic and/or endoscopic healing. The aim of this study was to assess the relationship between random serum ADA levels and histologic and endoscopic healing in patients with in...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000689

    authors: Yarur AJ,Jain A,Hauenstein SI,Quintero MA,Barkin JS,Deshpande AR,Sussman DA,Singh S,Abreu MT

    更新日期:2016-02-01 00:00:00

  • Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index.

    abstract:BACKGROUND:The aim of this study was to develop a shortened Crohn's Disease Activity Index (CDAI). METHODS:A short CDAI was developed retrospectively using patient-level data from four budesonide clinical trials to select variables from the full CDAI which best predicted health-related quality of life as measured by t...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21400

    authors: Thia K,Faubion WA Jr,Loftus EV Jr,Persson T,Persson A,Sandborn WJ

    更新日期:2011-01-01 00:00:00

  • Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

    abstract:BACKGROUND:Vedolizumab is a gut-selective biologic that has shown efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We studied the pharmacokinetics, pharmacodynamics, safety, tolerability, and efficacy of a new formulation of vedolizumab produced by an improved manufacturing process. METHODS:UC patients we...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21896

    authors: Parikh A,Leach T,Wyant T,Scholz C,Sankoh S,Mould DR,Ponich T,Fox I,Feagan BG

    更新日期:2012-08-01 00:00:00

  • Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

    abstract:BACKGROUND AND AIMS:Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200608000-00011

    authors: Fakhoury M,Lecordier J,Medard Y,Peuchmaur M,Jacqz-Agrain E

    更新日期:2006-08-01 00:00:00

  • Human β-defensin 3 peptide is increased and redistributed in Crohn's ileitis.

    abstract:BACKGROUND:Antimicrobial peptides (AMPs) maintain a sterile environment in intestinal crypts, limiting microbial colonization and invasion. Decreased AMP expression is proposed to increase the risk for inflammatory bowel disease. Expression and function of inducible AMPs, human β-defensin 2 and 3 (hBD-2 and hBD-3), rem...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318280b11a

    authors: Meisch JP,Nishimura M,Vogel RM,Sung HC,Bednarchik BA,Ghosh SK,Fu P,McCormick T,Weinberg A,Levine AD

    更新日期:2013-04-01 00:00:00

  • Immunoregulatory Pathways Involved in Inflammatory Bowel Disease.

    abstract::Inflammatory bowel diseases (IBD) include ulcerative colitis and Crohn's disease. The immune response in ulcerative colitis is different from the Crohn's disease. Accumulating evidence suggests that IBD results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. Severa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000477

    authors: Fonseca-Camarillo G,Yamamoto-Furusho JK

    更新日期:2015-09-01 00:00:00

  • Characterization of hepatic abnormalities in children with inflammatory bowel disease.

    abstract::: We sought to characterize the incidence, nature, and course of liver disease in children with inflammatory bowel disease (IBD). Chart review identified 555 subjects (318 Crohn's disease [CD], 237 ulcerative colitis [UC]). An alanine aminotransferase measurement of ≥80 U/L was used to identify the presence of a hepat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Hyams J,Markowitz J,Treem W,Davis P,Grancher K,Daum F

    更新日期:1995-04-01 00:00:00

  • Healing of intestinal inflammation by IL-22.

    abstract::An interleukin (IL)-10 family cytokine, IL-22 is characterized by several unique biological properties, including 1) the target restricted to innate cells; 2) the distinct expression pattern between large and small intestines; 3) alteration of the cellular source depending on several factors; 4) the dual abilities to ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.22929

    authors: Mizoguchi A

    更新日期:2012-09-01 00:00:00

  • TNFRSF1B Is Associated with ANCA in IBD.

    abstract::The genetic basis of antineutrophil cytoplasmic antibody, an important biomarker of inflammatory bowel disease (IBD), has never been thoroughly examined on a genome-wide scale. In this study, we performed a 2-stage genome-wide association study (GWAS) on antineutrophil cytoplasmic antibody in IBD cases. In the 2959 IB...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1097/MIB.0000000000000771

    authors: Li D,Silverberg MS,Haritunians T,Dubinsky MC,Landers C,Stempak JM,Milgrom R,Guo X,Chen YD,Rotter JI,Taylor KD,McGovern DP,Targan SR

    更新日期:2016-06-01 00:00:00

  • Increased Rates of Clostridium difficile Infection and Poor Outcomes in Patients with IBD with Cytomegalovirus.

    abstract:BACKGROUND:Clostridium difficile infection (CDI) and Cytomegalovirus (CMV) reactivation are associated with disease exacerbations and poor outcomes in inflammatory bowel disease (IBD). Therefore, we assessed the association between these organisms in patients with IBD and the impact on colectomy. METHODS:A retrospecti...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000939

    authors: McCurdy JD,Enders FT,Khanna S,Bruining DH,Jones A,Killian JM,Tariq R,Smyrk TC,Loftus EV Jr

    更新日期:2016-11-01 00:00:00

  • Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.

    abstract::Ulcerative colitis and Crohn's disease both confer an increased risk of developing colorectal cancer. The use of 5-aminosalicylate as a remission-inducing agent has been long accepted. Its use as a potential chemoprophylactic agent has been proposed and is used by some practitioners. This review examines the most rece...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20186

    authors: Levine JS,Burakoff R

    更新日期:2007-10-01 00:00:00

  • Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis.

    abstract::Clinical and epidemiological studies have revealed that the incidence of colorectal cancer associated with ulcerative colitis increases with long-term chronic inflammation. Careful endoscopic observation and histological studies to check for dysplasia in the colon are important in detecting neoplasia. Current surveill...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20267

    authors: Matsumoto T,Iwao Y,Igarashi M,Watanabe K,Otsuka K,Watanabe T,Iizuka B,Hida N,Sada M,Chiba T,Kudo SE,Oshitani N,Nagawa H,Ajioka Y,Hibi T

    更新日期:2008-02-01 00:00:00

  • Murine TNF(DeltaARE) Crohn's disease model displays diminished expression of intestinal Ca2+ transporters.

    abstract:BACKGROUND:Patients suffering from Crohn's disease (CD) show increased incidence of low bone mineral density. Investigating this complication is difficult because the exact etiology of CD remains elusive. Mice carrying a deletion in the tumor necrosis factor (TNF) AU-rich elements (ARE) are reported as a model for huma...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20385

    authors: Huybers S,Apostolaki M,van der Eerden BC,Kollias G,Naber TH,Bindels RJ,Hoenderop JG

    更新日期:2008-06-01 00:00:00

  • Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity.

    abstract:Background:The Crohn's Disease Activity Index (CDAI), a scoring index including patient-reported outcomes (PROs), has known limitations for measuring intestinal inflammatory disease burden. Noninvasive markers of inflammation could prove more accurate than PROs; thus, regulatory authorities are exploring the use of PRO...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izx018

    authors: Morris MW,Stewart SA,Heisler C,Sandborn WJ,Loftus EV,Zello GA,Fowler SA,Jones JL

    更新日期:2018-01-18 00:00:00

  • Genome-wide expression profiling implicates a MAST3-regulated gene set in colonic mucosal inflammation of ulcerative colitis patients.

    abstract:BACKGROUND:Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) presumably caused by dysregulated immune responses to the gut microbiota. Genetic association studies have implicated dozens of chromosomal regions or loci in IBD susceptibility. The next challenge is to explain the indiv...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21887

    authors: Labbé C,Boucher G,Foisy S,Alikashani A,Nkwimi H,David G,Beaudoin M,Goyette P,Charron G,Xavier RJ,Rioux JD

    更新日期:2012-06-01 00:00:00

  • Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood-Adulthood Transition.

    abstract::Gastrointestinal disorders, although clinically heterogeneous, share pathogenic mechanisms, including genetic susceptibility, impaired gut barrier function, altered microbiota, and environmental triggers (infections, social and behavioral factors, epigenetic control, and diet). Gut microbiota has been studied for infl...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000602

    authors: Putignani L,Del Chierico F,Vernocchi P,Cicala M,Cucchiara S,Dallapiccola B,Dysbiotrack Study Group.

    更新日期:2016-02-01 00:00:00

  • Predictors of fibrostenotic Crohn's disease.

    abstract::Intestinal fibrosis is a common and serious complication of Crohn's disease (CD) and as it can occur at any time during the disease course, it is crucial to identify patients at risk. The aim is not only to understand the pathophysiology of fibrogenesis but to be able to accurately inform subjects about their disease ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21627

    authors: Rieder F,Lawrance IC,Leite A,Sans M

    更新日期:2011-09-01 00:00:00